Search Results

CinRx Pharma today announced the closing of a $73 million financing, bringing the total funds raised to $176 million.

CinPhloro Pharma, a CinRx Portfolio Company, Dosed First Participant in Phase 2 enviva Study of CIN-103 for Irritable Bowel Syndrome with Predominant Diarrhea (IBS-D).

CinFina Pharma, CinRx Pharma’s portfolio company dedicated to expanding treatment options for obesity and metabolic diseases, announced the scientific advisory board members for the company’s multi-asset pipeline.

CinDome Pharma, a CinRx portfolio company dedicated to advancing a safe, chronic therapy for gastroparesis, today announced a $40 million Series B financing extension.

CinRx’s CinDome Pharma to Present a Poster on Deudomperidone (CIN-102) at 2023 Digestive Disease Week ® Conference.

CinFina Pharma, a CinRx portfolio company dedicated to advancing a portfolio of high-impact treatment options for obesity and metabolic diseases, today announced the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug Application (IND) for CIN-110, a PYY3-36 analog, allowing the first in-human clinical study to proceed.

CinRx Pharma today announced that the first study participant has been dosed in CinDome Pharma’s Phase 2 envision3D study of deudomperidone (CIN-102) in patients with diabetic gastroparesis.

CinDome Pharma, a CinRx portfolio company, presented a poster at the 2023 Digestive Disease Week Conference titled “Effect of Therapeutic and Supratherapeutic Doses of Deudomperidone on Cardiac Repolarization in a Thorough QT Study in Healthy Subjects.”

An appreciation for practicality, independent thinking and patient care can help disrupt the bureaucracy of Big Pharma.

Astellas Pharma’s new life sciences center houses its first U.S.-based SakuLab, an incubator space for external partners, as well as its engineered small molecules unit.